Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02389764 · ClinicalTrials.gov registry record · Phase 2
Nintedanib For HER2-Negative Metastatic Inflammatory Breast Cancer (MIBC)
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT02389764: Clinical Trial Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT02389764 is a Phase 2 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02389764, a Phase 2 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if Ofev® (nintedanib, also called BIBF1120) can help to control IBC. The safety of this drug will also be studied. This is an investigational study. Nintedanib is commercially available and FDA approved for the treatment of certain types of lung disease. Its use in this study is investigational. The study doctor can explain how the study drug is designed to work. Up to 44 participants will be enrolled in this study. All will take part at MD Anderson.
Interventions
- BEHAVIORAL Phone Call
- DRUG BIBF 1120
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2015-06-22 |
| Est. Completion | 2019-06-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02389764
The ClinicalTrials.gov registry entry for NCT02389764 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Phone Call is the first listed.
NCT02389764 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02389764 about?
NCT02389764 is a clinical study titled "Nintedanib For HER2-Negative Metastatic Inflammatory Breast Cancer (MIBC)". The goal of this clinical research study is to learn if Ofev® (nintedanib, also called BIBF1120) can help to control IBC. The safety of this drug will also be studied. This is an investigational study. Nintedanib is commercially available and FDA approved for the treatment of certain types of lung ...
What is the current status of trial NCT02389764?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2015-06-22. Estimated completion is 2019-06-08.
What interventions are being tested in trial NCT02389764?
The interventions under investigation include: Phone Call (BEHAVIORAL), BIBF 1120 (DRUG).
Who is sponsoring clinical trial NCT02389764?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.